Market Overview:
The global opioids agonist drugs industry is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic pain, rising geriatric population, and growing demand for pain management drugs. In terms of type, the codeine segment is expected to lead the market during the forecast period owing to its high usage in cough treatment and diarrhea treatment applications. However, fentanyl is projected to grow at a higher CAGR due to its high potency and widespread use in pain management applications. Geographically, North America dominates the global opioids agonist drugs industry followed by Europe and Asia Pacific.
Product Definition:
An opioid is a chemical that binds to opioid receptors in the brain, spinal cord, and other organs in the body. Opioid agonist drugs are synthetic versions of opium alkaloids such as morphine and codeine. They relieve pain by acting on these receptors.
Codeine:
Codeine is an opioid drug. Opioids agonist drugs are used to treat pain and cough-related conditions. The global codeine's usage and growth factor in the opioid agonist drugs industry was valued at USD 1,09,000 million in 2016 which is expected to grow at a CAGR of XX% over the forecast period of 2017-2022.
Fentanyl:
Fentanyl is an opioid drug, which is commonly used to treat breakthrough pain in cancer patients. It is a strong synthetic analgesic that affects the Central Nervous System (CNS), causing euphoria and relaxation. The drug has several side effects such as nausea, vomiting, and constipation; these side effects make it unsuitable for use in patients with kidney or liver disease.
Application Insights:
The pain management segment dominated the global opioids agonist drugs industry in 2017, owing to the rising prevalence of chronic pain disorders. According to a study published in The Journal of Pain, chronic pain affected around 40 million adults in the U.S., making it one of the country¢â‚¬â„¢s major health problems. Furthermore, another study states that approximately 20% to 30% of patients visiting primary care physicians have acute pain and related symptoms.
Regional Analysis:
North America dominated the global industry in 2017, owing to the presence of a large patient pool and well-established healthcare infrastructure. The region is expected to maintain its dominance throughout the forecast period on account of high product consumption and availability of advanced treatment options. In addition, rising incidence rates of chronic pain conditions are anticipated to drive regional market growth over the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions during the same year due to increasing government initiatives for opioid substitution therapy coupled with growing awareness about these drugs among patients suffering from addiction or abuse issues. Moreover, economic development in this region has led to an increase in disposable income which will further boost demand for OAT products over next eight years. Favorable regulatory policies framed by governments across various countries are also contributing toward regional growth rate by allowing easy access & availability OAT products at affordable prices (codeine cough syrup sells for USD X).
Growth Factors:
- Increasing prevalence of chronic pain: The global prevalence of chronic pain is estimated to be around 20%. This number is expected to grow as the population ages. Opioids are one of the most effective treatments for chronic pain.
- Rising awareness about opioids: There has been a growing awareness about the benefits and risks of opioids in recent years. This has led to an increase in prescriptions for opioid agonist drugs.
- Growing demand for abuse-deterrent formulations: Opioid agonist drugs are often abused by people who want to get high. There is a growing demand for abuse-deterrent formulations that make it harder to misuse these drugs.
Scope Of The Report
Report Attributes
Report Details
Report Title
Opioids Agonist Drugs Industry Market Research Report
By Type
Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone
By Application
Pain Management, Cough Treatment, Diarrhea Treatment
By Companies
Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, Pfizer Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Opioids Agonist Drugs Industry Market Report Segments:
The global Opioids Agonist Drugs Industry market is segmented on the basis of:
Types
Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pain Management, Cough Treatment, Diarrhea Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Purdue Pharma
- Titan pharmaceuticals
- Boehringer Ingelheim
- Janssen Pharmaceuticals, Inc
- Sanofi
- Sun Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Egalet Corporation
- Endo Pharmaceuticals Inc.
- Allergan, Plc
- Pfizer Inc
Highlights of The Opioids Agonist Drugs Industry Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Codeine
- Fentanyl
- Meperidine
- Methadone
- Morphine
- Hydrocodone
- By Application:
- Pain Management
- Cough Treatment
- Diarrhea Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Opioids Agonist Drugs Industry Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Opioid agonist drugs are medications that bind to opioid receptors in the brain and spinal cord, mimicking the effects of opioids like morphine and codeine. These drugs can relieve pain by blocking signals from the brain to the bodyu2019s nerves.
Some of the key players operating in the opioids agonist drugs industry market are Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, Pfizer Inc.
The opioids agonist drugs industry market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Opioids Agonist Drugs Industry Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Opioids Agonist Drugs Industry Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Opioids Agonist Drugs Industry Market - Supply Chain
4.5. Global Opioids Agonist Drugs Industry Market Forecast
4.5.1. Opioids Agonist Drugs Industry Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Opioids Agonist Drugs Industry Market Size (000 Units) and Y-o-Y Growth
4.5.3. Opioids Agonist Drugs Industry Market Absolute $ Opportunity
5. Global Opioids Agonist Drugs Industry Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Opioids Agonist Drugs Industry Market Size and Volume Forecast by Type
5.3.1. Codeine
5.3.2. Fentanyl
5.3.3. Meperidine
5.3.4. Methadone
5.3.5. Morphine
5.3.6. Hydrocodone
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Opioids Agonist Drugs Industry Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Opioids Agonist Drugs Industry Market Size and Volume Forecast by Application
6.3.1. Pain Management
6.3.2. Cough Treatment
6.3.3. Diarrhea Treatment
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Opioids Agonist Drugs Industry Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Opioids Agonist Drugs Industry Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Opioids Agonist Drugs Industry Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Opioids Agonist Drugs Industry Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Opioids Agonist Drugs Industry Demand Share Forecast, 2019-2026
9. North America Opioids Agonist Drugs Industry Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Opioids Agonist Drugs Industry Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Opioids Agonist Drugs Industry Market Size and Volume Forecast by Application
9.4.1. Pain Management
9.4.2. Cough Treatment
9.4.3. Diarrhea Treatment
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Opioids Agonist Drugs Industry Market Size and Volume Forecast by Type
9.7.1. Codeine
9.7.2. Fentanyl
9.7.3. Meperidine
9.7.4. Methadone
9.7.5. Morphine
9.7.6. Hydrocodone
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Opioids Agonist Drugs Industry Demand Share Forecast, 2019-2026
10. Latin America Opioids Agonist Drugs Industry Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Opioids Agonist Drugs Industry Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Opioids Agonist Drugs Industry Market Size and Volume Forecast by Application
10.4.1. Pain Management
10.4.2. Cough Treatment
10.4.3. Diarrhea Treatment
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Opioids Agonist Drugs Industry Market Size and Volume Forecast by Type
10.7.1. Codeine
10.7.2. Fentanyl
10.7.3. Meperidine
10.7.4. Methadone
10.7.5. Morphine
10.7.6. Hydrocodone
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Opioids Agonist Drugs Industry Demand Share Forecast, 2019-2026
11. Europe Opioids Agonist Drugs Industry Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Opioids Agonist Drugs Industry Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Opioids Agonist Drugs Industry Market Size and Volume Forecast by Application
11.4.1. Pain Management
11.4.2. Cough Treatment
11.4.3. Diarrhea Treatment
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Opioids Agonist Drugs Industry Market Size and Volume Forecast by Type
11.7.1. Codeine
11.7.2. Fentanyl
11.7.3. Meperidine
11.7.4. Methadone
11.7.5.Morphine
11.7.6. Hydrocodone
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Opioids Agonist Drugs Industry Demand Share, 2019-2026
12. Asia Pacific Opioids Agonist Drugs Industry Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Opioids Agonist Drugs Industry Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Opioids Agonist Drugs Industry Market Size and Volume Forecast by Application
12.4.1. Pain Management
12.4.2. Cough Treatment
12.4.3. Diarrhea Treatment
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Opioids Agonist Drugs Industry Market Size and Volume Forecast by Type
12.7.1. Codeine
12.7.2. Fentanyl
12.7.3. Meperidine
12.7.4. Methadone
12.7.5. Morphine
12.7.6. Hydrocodone
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Opioids Agonist Drugs Industry Demand Share, 2019-2026
13. Middle East & Africa Opioids Agonist Drugs Industry Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Opioids Agonist Drugs Industry Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Opioids Agonist Drugs Industry Market Size and Volume Forecast by Application
13.4.1. Pain Management
13.4.2. Cough Treatment
13.4.3. Diarrhea Treatment
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Opioids Agonist Drugs Industry Market Size and Volume Forecast by Type
13.7.1. Codeine
13.7.2. Fentanyl
13.7.3. Meperidine
13.7.4. Methadone
13.7.5. Morphine
13.7.6. Hydrocodone
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Opioids Agonist Drugs Industry Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Opioids Agonist Drugs Industry Market: Market Share Analysis
14.2. Opioids Agonist Drugs Industry Distributors and Customers
14.3. Opioids Agonist Drugs Industry Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Purdue Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Titan pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Janssen Pharmaceuticals, Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sun Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Mallinckrodt Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Egalet Corporation
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Endo Pharmaceuticals Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Allergan, Plc
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Pfizer Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
